Value-based healthcare in Spain: Regional experimentation in a shared governance setting

Value-based healthcare in Spain: Regional experimentation in a shared governance setting is an Economist Intelligence Unit (EIU) report, commissioned by Gilead Sciences. It looks at health outcomes of treatment relative to cost and at the structure of Spanish healthcare delivery, the process of making healthcare more accountable in Spain, and the growth and adoption of value-based measures.

Martin Koehring
Martin Koehring
Senior Manager for Sustainability, Climate Change and Natural Resources & Head of the World Ocean Initiative, Economist Enterprise

3 Nov 2015

Value-based healthcare in Spain: Regional experimentation in a shared governance setting

Spain’s decentralised National Health System grants financial, planning and management powers to the regional health services of the country’s 17 autonomous communities and two autonomous cities. In addition the regions also have more responsibility for the appraisal of treatments and care pathways, and for final price negotiations with drug manufacturers.

This paper will show that the process of making healthcare more accountable in Spain is evolving in a number of ways but the growth and adoption of value-based measures remain fragmented. This is largely due to the decentralised administration of healthcare in the country.

Download Full Report

Further reading:


Value-based healthcare in the UK: A system of trial and error
Supported by Gilead and Kite

Value-based healthcare in the UK: A system of trial and error

This Economist Intelligence Unit (EIU) report, commissioned by Gilead Sciences, explores important questions about the UK healthcare system.

Value-based healthcare in Portugal: Necessity is the mother of invention
Supported by Gilead and Kite

Value-based healthcare in Portugal: Necessity is the mother of invention

This paper examines how the recent economic crisis has shaped health technology assessment; the role of the hospital sector; and promising initiatives in integrated care, family health units and a new process for the re-evaluation of health technologies.

Value-based healthcare in France: A slow adoption of cost-effectiveness criteria
Supported by Gilead and Kite

Value-based healthcare in France: A slow adoption of cost-effectiveness criteria

This new Economist Intelligence Unit (EIU) report, commissioned by Gilead Sciences, explores important questions about the French healthcare system. How is healthcare innovation assessed in France? To what extent is value for money influencing price neg

Value-based Healthcare in Germany: From free price-setting to a regulated market
Supported by Gilead and Kite

Value-based Healthcare in Germany: From free price-setting to a regulated market

This report looks at the evolution of health technology assessment and pharmaceutical pricing reform in Germany and examines the new focus on providers and health outcomes.